Catenaa, Wednesday, December 03, 2025- Lite Strategy Inc. reported first-quarter fiscal 2026 results, highlighting the launch of a $100 million Litecoin (LTC) treasury strategy and expansion into active capital market operations.
The company now holds 929,548 LTC tokens, making it the first US publicly traded firm with institutional exposure to Litecoin.
The quarter saw the completion of a $100 million PIPE offering and the sale of its clinical asset ME-344, now known as WE-868, supporting the company’s pivot from pharmaceutical operations to digital asset treasury management.
Lite Strategy also rebranded from MEI Pharma to LITS, updated its NASDAQ ticker, and unveiled a new logo and website to reflect its focus on LTC as a primary reserve asset.
LITS entered a strategic partnership with GSR to guide its Litecoin treasury strategy, ensuring governance, execution, and market expertise.
In October, the company announced a $25 million share repurchase program, marking a move from asset accumulation to active capital market engagement.
Board members include Litecoin creator Charlie Lee and GSR US Chief Strategy Officer Joshua Riezman, reinforcing the company’s expertise in both digital assets and corporate governance. As of September 30, 2025, Lite Strategy held $12.21 million in working capital with no outstanding debt.
CEO Jay File said the company will continue evaluating clinical assets, including preclinical studies with voruciclib and potential licensing of zandelisib, while executing the share buyback program and LTC treasury strategy.
